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E D I T O R I A L

Defining patient value in haemophilia care
Once upon a time, before the age of modern medicine, death ór miraculous survival was the most common outcome for many diseases, including haemophilia. Nowadays, haemophilia outcomes also include bleeding episodes, arthropathy and inhibitors, and more patient-centred outcomes such as quality of life (QoL) and participation in society. There is no doubt that these outcomes have improved dramatically in most countries in the past decades, due to increased availability of safe clotting factor concentrates and prophylactic treatment. But has "value" for individuals with haemophilia increased? If so, can the haemophilia community worldwide improve "value" further? And will "value" increase with novel and promising, The second step is to establish so-called minimum outcomes sets or core sets of outcomes (both clinical and patient-reported).
These combined sets have already been developed for several conditions, including lower back pain, 6 advanced prostate cancer 7 and hip and knee osteoarthritis. 8 With the help of Delphi-like processes and involvement of both patients and different clinical specialists, organizations such as the International Consortium for Health Outcomes Measurement (ICHOM) and the Core Outcome Measures in Effectiveness Trials (COMET) focus on defining outcomes that matter most to patients and that are to be used as effectiveness endpoints in clinical trials, 9 with the patient's voice becoming increasingly important.
10
As with value, outcomes are not all similar and equal, but they form a hierarchy. 1 Porter divides patient-relevant outcomes into three tiers: (i) health status achieved or retained, for example mortality rates or functional status; (ii) outcomes related to the nature of the care cycle and recovery, for example preventing hospital readmissions, because they are a burden on patients and clinicians as well as on the system; and (iii) outcomes related to the sustainability of health, for example recurrence of health problems. 3 A core set of combined clinical and patient-reported outcomes does not yet exist
